Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.
